“LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT” (2024) Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024039. doi:10.4084/MJHID.2024.039.